Page 48 - CIBEREHD2016-ENG

LEAD rESEArCHEr
Berenguer Haym, Marina
Fund.para la Investigación
del Hospital La Fe
Hospital Universitario de La Fe Avda Fernando Abril Martorell, 106, Torre A, planta 5, Lab 5.30 46026 Valencia
group Website
GROUP MEMBERS
Staff members: Carvalho Gomes, Ángela Sofía | Pallarés Alejandro, Carmina
Associated members: Aguilera Tello, Victoria | Benlloch Pérez, Salvador | Pérez Rojas, Judith | Prieto Castillo, Martín | Rubín Suárez, Ángel
Main lines of research
• Hepatitis B, C, D and E (clinical, virological and immunological studies) Focus on assessing the effectiveness and risk-benefit of new direct-acting antivirals for the treatment of HCV (and to a lesser extent HBV/HDV) both in immunocompetent and liver transplant patients (pre and posttransplant). Studies performed usually within clinical trials sponsored by industry. We also collaborate in national and international real life cohorts. Collaboration with national and international groups aimed at defining the point of no return in patients with advanced disease. These studies/collaborations have resulted in several publications in first decile journals (some in preparation) and guidelines (national and international) regarding the treatment of HCV. We are leading a multicenter study ( FIS project ) assessing interactions between HCV and other viruses, such as CMV. Finally, we have obtained private and public funding for epidemiological studies on the prevalence of HCV infection and selection of cost- effective screening strategies.
• Post-liver transplantation (LT) long-term complications. research to study several post-TH complications such as sexual and renal function, diabetes, cardiovascular disease and de novo tumors. These studies have resulted in publications in first decile journals. Likewise, we collaborate with other centers to determine prognostic factors for cellular rejection and operational mechanisms involved in tolerance.
48
PROGRAMMES
P1